EUREKA THERAPEUTICS ANNOUNCES UPCOMING CONFERENCE PRESENTATIONS
Emeryville, California, March 3, 2020 – Eureka Therapeutics, Inc., a clinical stage biotechnology company developing novel T cell therapies to treat solid tumors, today announced that the company is scheduled to present at the following March healthcare conferences:
Cowen 40th Annual Health Care Conference
Title: ARTEMIS® Antibody TCR T Cell Therapies for Solid Tumors
Speaker: Hanzhong Li, Ph.D., Senior Vice President of Corporate Strategy
Location: Boston Marriott Copley Place, Boston, MA
Date: Wednesday, March 4, 2020
Time: 8:30 a.m. EST
BioProcess International US West
Title: Optimizing Viral Vector Production
Speaker: Nicole Nunez, Ph.D., Process Development Scientist
Location: Santa Clara Convention Center, Santa Clara, CA
Date: Wednesday, March 11, 2020
Time: 1:05 p.m. PST
About Eureka Therapeutics, Inc.
Eureka Therapeutics, Inc. is a privately held clinical stage biotechnology company focused on developing novel T cell therapies to treat cancers. Its core technology centers around its proprietary ARTEMIS® AbTCR T cell receptor platform and E-ALPHA® antibody discovery platform for the discovery and development of potentially safer and more effective T cell therapies for the treatment of solid tumors and hematologic malignancies. ET140202, the Company’s lead asset, is currently in a Phase I/II US multicenter clinical trial in patients with advanced hepatocellular carcinoma (HCC).
Eureka Therapeutics, Inc. is headquartered in the San Francisco Bay Area. For more information on Eureka, please visit www.eurekatherapeutics.com.